heart failure (ADHF) from other syndroms. Our aim was to get insights into the pathophysiological conditions leading to altered expression of QSOX1 through the use of HF model rats.
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The effect of bisoprolol on right ventricular function in a cohort of 60 patients with chronic heart failure Hasnaa Salih [Orateur] , Roger Kongo, Nouhad Jardi, Fatima Belmourida, Leila Azzouzi, Ahmed Bennis
CHU Ibn Rochd, Casablanca, Maroc
Beta-blocker use improves left ventricular ejection fraction (LVEF) in patients with heart failure. A similar effect of beta-blockers on right ventricular function has been proposed, although the effect of Bisoprolol on right ventricular function has not been assessed.
This study investigated the short-term effect of Bisoprolol on right ventricular function in chronic heart failure patients. A cohort of 60 heart failure patients who were not taking beta-blockers at baseline was studied prospectively. Right ventricular ejection fraction (RVEF) and LVEF were measured at both baseline and 6 months by echocardiography. Various parameters of the right ventricular function were measured: Simpson RVEF, surface shortening fraction, right ventricular outflow tract (RVOT %), TAPSE (mm), S' wave with tissue doppler (S' dti cm/s), and the Tei index. The threshold of significativity was fixed at 5%. Bisoprolol was up titred during six months by a preestablished protocol to a target dose of 10 mg/ Od. Mean age was 65.7±16.3 years. Baseline RVEF was 25.6±5.2% and baseline LVEF was 20.8±6.4%. Mean Bisoprolol dose reached was 25±12.5 mg daily. At 12 months, RVEF was significantly increased by 7.5% (95% confidence interval, 3.9-10.2; p=0.0001) and LVEF also increased significantly by 7.5% (95% confidence interval, 4.0%-11.9%; p=0.0003). All the parameters of the right ventricular function were significantly improved: TAPSE (15.5 vs 12.7; p=0.078), Doppler S'dti cm/s (10.7 vs 8.2; p=0.002), tei index (54.10vs 81.45; p=0.0008, RVOT% (27.1 vs 19.3; p=0.036), dp/dt RV (721vs 505; p=0.05).
The efficacy and good tolerance of bisoprolol is demonstrated in this study on chronic heart failure with right ventricular dysfunction when administered in a precise pattern
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Emergency extra-corporeal membrane oxygenation in cardiac shock and cardiac arrest in hospital without on-site cardiac surgical facilities Purpose: Emergency extra-corporeal membrane oxygenation (ECMO) implantation for severe cardiac shock or refractory cardiac arrest (under cardiac massage), conducted in hospitals with on-site cardiac surgical facilities, has been reported as both safe and effective. We report the feasibility, in-hospital complications and outcomes of ECMO implantation, in a local hospital without on-site cardiac surgical facilities.
Methods: This single-centre, prospective, consecutive cohort study involved 50 pts who had ECMO implantation (2006) (2007) (2008) (2009) (2010) . Of these pts, 26 were in severe cardiac shock and 24 in refractory cardiac arrest. Implantations were done by an interventional cardiologist team available 24/7, and in collaboration with the nearest cardiac surgical institution, located 100 km away, to which patients were transferred subsequently.
Results: Stable ECMO implantation was achieved in 89% of pts in severe cardiac shock and in 79% in refractory cardiac arrest. In-hospital complications occurred in 20/23 pts in cardiac shock and 13/23 were discharged alive. In-hospital complications occurred in 18/19 pts in refractory cardiac arrest and 1/19 was discharged alive.
Conclusion:
In a hospital with no cardiac surgical facilities, rates of implantation failure, initial complications, and hospital outcomes in pts who had ECMO implantation for severe cardiac shock or refractory cardiac arrest were concordant with previous reports from hospitals with cardiac surgical facilities. We observed a low rate of survival among implanted pts in refractory cardiac arrest. Chemoreflex-mediated sympathetic activation contributes to both initiation and progression of chronic heart failure (CHF).
